Literature DB >> 15910595

Ki67 and p53 immunohistochemistry reduces interobserver variation in assessment of Barrett's oesophagus.

E Lörinc1, B Jakobsson, G Landberg, B Veress.   

Abstract

AIMS: To devise clinically applicable methods for assessing p53 and Ki67 immunohistochemical (IHC) reactivity in Barrett's oesophagus (BE) and to compare the interobserver agreement between these methods and routine haematoxylin and eosin (H&E) evaluation. METHODS AND
RESULTS: One hundred and fifteen biopsies diagnosed as BE, selected from the files of the University Hospital MAS, Malmo, were re-evaluated for dysplasia by three pathologists. For IHC analysis areas with the most prominent positivity were evaluated. The mean of p53+ epithelial nuclei/high-power field (HPF) was obtained by counting between 1 and 5 HPFs/biopsy. A proliferation quotient (PQ) was obtained by dividing the number of Ki67+ epithelial nuclei in the upper half by the lower half of the mucosa, using two HPFs. Mean kappa values were 0.24, 0.71 and 0.52 for H&E, p53 and Ki67 evaluations, respectively. There was a correlation between increasing severity of dysplasia, IHC measurable overexpression of p53 and shift of the mucosal proliferation zone towards the surface, measured as PQ.
CONCLUSIONS: The described methods for p53 and Ki67 evaluation are more reproducible than routine H&E evaluation of BE. Furthermore, the IHC methods correlate with the severity of dysplasia and are useful supplementary prognostic markers.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15910595     DOI: 10.1111/j.1365-2559.2005.02139.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  7 in total

1.  Defining Cancer Risk in Barrett's Esophagus: A Pathologist's Perspective.

Authors:  Amy E Noffsinger
Journal:  Gastrointest Cancer Res       Date:  2008-11

2.  Evidence for DNA damage checkpoint activation in barrett esophagus.

Authors:  Urs von Holzen; Tina Chen; Amelie Boquoi; Joel E Richter; Gary W Falk; Andres J Klein-Szanto; Harry Cooper; Sam Litwin; David S Weinberg; Greg H Enders
Journal:  Transl Oncol       Date:  2010-02       Impact factor: 4.243

Review 3.  Diagnosis and grading of dysplasia in Barrett's oesophagus.

Authors:  R D Odze
Journal:  J Clin Pathol       Date:  2006-10       Impact factor: 3.411

4.  A personalized and dynamic risk estimation model: The new paradigm in Barrett's esophagus surveillance.

Authors:  Carlijn A M Roumans; Manon C W Spaander; Iris Lansdorp-Vogelaar; Katharina Biermann; Marco J Bruno; Ewout W Steyerberg; Dimitris Rizopoulos
Journal:  PLoS One       Date:  2022-04-27       Impact factor: 3.752

5.  Barrett's Esophagus: Emerging Knowledge and Management Strategies.

Authors:  Atul Bhardwaj; Thomas J McGarrity; Douglas B Stairs; Haresh Mani
Journal:  Patholog Res Int       Date:  2012-05-30

6.  Concomitant use of heat-shock protein 70, glutamine synthetase and glypican-3 is useful in diagnosis of HBV-related hepatocellular carcinoma with higher specificity and sensitivity.

Authors:  Bita Moudi; Zahra Heidari; Hamidreza Mahmoudzadeh-Sagheb; Seyed-Moayed Alavian; Kamran B Lankarani; Parisa Farrokh; Jens Randel Nyengaard
Journal:  Eur J Histochem       Date:  2018-01-29       Impact factor: 3.188

Review 7.  Barrett's esophagus: The pathomorphological and molecular genetic keystones of neoplastic progression.

Authors:  Ksenia S Maslyonkina; Alexandra K Konyukova; Darya Y Alexeeva; Mikhail Y Sinelnikov; Liudmila M Mikhaleva
Journal:  Cancer Med       Date:  2021-12-06       Impact factor: 4.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.